Diagnosis & Disease Information

KALYDECO (ivacaftor) 150mg tablets by Vertex

Kalydeco Gains Expanded Cystic Fibrosis Indication

The FDA has approved a sNDA for Kalydeco (ivacaftor; Vertex) for use in patients with cystic fibrosis (CF) ages >6 years old who have 1 of 8 additional mutations in the CF transmembrane conductance regulator (CFTR) gene.